Comparing Arrayit (OTCMKTS:ARYC) & Pulse Biosciences (NASDAQ:PLSE)

Arrayit (OTCMKTS:ARYC) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Arrayit and Pulse Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrayit	N/A	N/A	N/A
Pulse Biosciences	N/A	-86.67%	-73.61%

Earnings and Valuation

This table compares Arrayit and Pulse Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrayit	N/A	N/A	N/A	N/A	N/A
Pulse Biosciences	$350,000.00	4,878.32	-$72.78 million	($1.10)	-22.43

Arrayit has higher earnings, but lower revenue than Pulse Biosciences.

Risk and Volatility

Arrayit has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Arrayit and Pulse Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrayit	0	0	0	0	0.00
Pulse Biosciences	1	0	2	0	2.33

Pulse Biosciences has a consensus target price of $30.00, indicating a potential upside of 21.61%. Given Pulse Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Arrayit.

Insider & Institutional Ownership

77.0% of Pulse Biosciences shares are owned by institutional investors. 58.0% of Arrayit shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Pulse Biosciences beats Arrayit on 7 of the 9 factors compared between the two stocks.

About Arrayit

Arrayit Corporation, a life sciences technology company, develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics worldwide. The company is involved in the development and support of microarray tools and components; custom printing and analysis of microarrays for research; and the identification and development of diagnostic microarrays and tools for early detection of treatable disease states. It offers microarray printing technology, which allows the manufacture of DNA, protein, antibody, lipid, carbohydrate, and other types of microarrays for research and diagnostic applications, including gene expression, genotyping, protein profiling, and others. The company also provides automated microarray manufacturing instruments, including NanoPrint, SpotBot Titan, SpotBot Extreme, SpotBo Protein, and Personal microarrayers, as well as SpotLight CCD fluorescence scanners, SpotWare colorimetric scanners, InnoScan laser scanners, TrayMix hybridization stations, ArrayMix hybridization stations, centrifuges, air jets, vacuum products, and laboratory tools and bioinformatics computers. In addition, it manufactures consumables, such as glass substrates and slides, reagents, solutions, kits, and clean room supplies; and provides variation identification platform technology that allows diagnostic tests to be performed by depositing approximately 100,000 patient samples onto a single microarray. Further, the company is involved in the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation offers its tools and services to genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies. The company is headquartered in Sunnyvale, California.

About Pulse Biosciences

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.